Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09–09): a randomised, open-label, multicentre, phase 3 trial - Döhner, H; Weber, D; Krzykalla, J (The Lancet Haematology, 2023)